DanNuo Medicine (Suzhou) Co., Ltd., a biotech company focused on bacterial infections and diseases related to bacterial metabolism, submitted a listing application to the Hong Kong Stock Exchange on February 3, 2026, aiming for a main board listing. CITIC Securities and ABCI are acting as joint sponsors.

As an innovative pharmaceutical company approaching the commercialization stage, DanNuo has built a differentiated pipeline comprising seven drug candidates. Its core product, TNP-2198, has completed Phase III clinical trials and is preparing a New Drug Application (NDA). It has the potential to become the world's first new molecular entity drug targeting Helicobacter pylori infection. However, the company has not yet achieved product commercialization or revenue, reporting continuous losses during the reporting period and reliance on external financing. Multiple risks in the commercialization process also warrant attention.

The company's pipeline includes three exclusive innovative drugs targeting unmet clinical needs. Established in 2013, DanNuo's core business focuses on R&D for innovative drugs related to bacterial infections and bacterial metabolism. Its product pipeline consists of seven innovative assets across stages nearing commercialization, late-stage clinical, IND-approved, and preclinical. The three core/major products are first-in-class innovative drug candidates addressing unmet needs, with current competition mainly from traditional off-label therapies or conventional drugs in the same field, and no direct competition from innovative drugs with the same mechanism.

TNP-2198, the most advanced core product, is the first and only new molecular entity candidate drug globally nearing commercialization for H. pylori infection since the bacterium's discovery in 1982. It is formed by conjugating rifamycin and nitroimidazole pharmacophores, simultaneously inhibiting bacterial RNA polymerase and nitroreductase. This dual-target synergistic mechanism provides bactericidal effects effective against both microaerophilic and anaerobic bacteria, potentially overcoming antimicrobial resistance.

According to the prospectus, the product has completed a China Phase III head-to-head clinical trial comparing it to Bismuth Quadruple Therapy (BQT). Results showed an eradication rate exceeding 90%, demonstrating significant superiority in multidrug-resistant populations, with safety and tolerability superior to the existing first-line BQT therapy. Furthermore, it does not require prior drug susceptibility testing, can be seamlessly integrated with urea breath tests (UBT), offers convenient dosing, and has significant patient compliance advantages.

TNP-2198 has submitted an NDA to the National Medical Products Administration (NMPA), which has been accepted, with approval expected by the end of 2026. In the US, it has received IND clearance, Fast Track designation, and Qualified Infectious Disease Product (QIDP) designation, potentially benefiting from FDA accelerated review. Beyond H. pylori infection, the company plans to advance its clinical development for bacterial vaginosis and Clostridioides difficile infection.

H. pylori infection is a major public health challenge, classified by the WHO as a Group I carcinogen, associated with approximately 80% of gastric cancer cases. Data from Frost & Sullivan indicates 621.1 million infected individuals in China in 2024, and 4.081 billion globally. Existing treatments face severe drug resistance issues. DanNuo's Phase III trial data shows resistance rates in treatment-naïve patients for clarithromycin, metronidazole, and levofloxacin at 40.8%, 68.2%, and 35.1% respectively. Resistance to at least one guideline-recommended antibiotic was 85.1%, with a multidrug resistance rate of 46.3%, indicating a substantial market replacement opportunity for TNP-2198.

TNP-2092 injection is a first-in-class three-target antibacterial candidate drug. Formed by conjugating rifamycin and quinolizinone pharmacophores, it simultaneously inhibits bacterial RNA polymerase, DNA gyrase, and topoisomerase IV. It is expected to be effective against biofilm infections at clinically achievable doses, specifically targeting implant-related bacterial infections like prosthetic joint infection (PJI) and acute bacterial skin and skin structure infections (ABSSSI).

The prospectus indicates TNP-2092 injection has received IND approval from the NMPA and FDA for treating PJI and ABSSSI. Six clinical trials have been completed in China and the US, including two Phase I trials, three clinical pharmacology trials, and one Phase II trial. In a US Phase II trial for ABSSSI, TNP-2092 demonstrated superior efficacy compared to vancomycin, with an early clinical response rate of 76.9% in the mITT population versus 67.5% for vancomycin. The advantage was more pronounced against resistant strains: early clinical response rates for methicillin-resistant Staphylococcus aureus (MRSA) were 78.1% (vancomycin 57.9%) and for quinolone-resistant Staphylococcus aureus (QRSA) 75.9% (vancomycin 55.6%).

A tissue distribution study in patients undergoing total hip/knee replacement showed TNP-2092 achieves high concentrations in synovial fluid and bone tissue, expected to exceed the minimum biofilm bactericidal concentration for 90% of PJI clinical isolates (MBBC₉₀), suggesting potential for infection control without surgery.

The market for implant-related bacterial infections is urgent, driven by advances in medical technology and an aging population. Traditional antibiotics struggle to penetrate bacterial biofilms, limiting treatment efficacy. Frost & Sullivan data projects global PJI incidence will increase from 86,400 cases in 2024 to 425,800 by 2035, with a CAGR of 13.8% from 2024-2029 and 17.1% from 2029-2035. In China, PJI incidence is expected to rise from 22,500 cases in 2024 to 86,500 by 2035, a CAGR of 11.7%. As of the latest practicable date, no innovative antibacterial drugs are approved globally for PJI treatment, giving TNP-2092, as the only small molecule candidate in clinical development, a significant first-mover advantage.

The main product TNP-2092 oral formulation is the first multi-target antibacterial candidate drug for treating intestinal flora metabolism-related diseases, targeting indications like hepatic encephalopathy (HE) and diarrhea-predominant irritable bowel syndrome (IBS-D). Its mechanism is similar to rifaximin (acting locally in the gut with minimal systemic exposure) but with superior activity against gut ammonia-producing bacteria, higher selectivity for probiotics, and very low spontaneous resistance frequency.

Clinical data shows TNP-2092 oral is more effective than rifaximin in reducing blood ammonia, a key trigger for HE development, giving it significant competitiveness. The product has completed four Phase I/II trials in China, with proof-of-concept data validating efficacy and safety.

Market size estimates for 2024 indicate 1.7 million HE prevalent cases in China and 9.3 million globally. IBS-D affected 119.9 million patients in China and 489.7 million globally. Rifaximin, a current standard, had global sales of $2 billion in 2024, but it is not approved in mainland China for HE or IBS-D and has a relatively high resistance frequency. TNP-2092 oral could potentially replace it with better efficacy and safety.

Beyond these three core/major products, DanNuo's pipeline includes TNP-2092 topical formulation, TNBi-1 (a novel small molecule drug), TNBi-2 (a multi-target conjugate drug), and TNBm-1 (a bifunctional small molecule drug).

The TNP-2092 topical formulation targets diabetic foot infections, showing strong bactericidal activity against resistant strains like MRSA and QRSA and biofilm-related infections. It has received IND approval in China, with Phase I/II trials expected to start in 2027.

TNBi-1, a novel small molecule, works by targeting H. pylori's electron transport chain to weaken ATP synthesis, with no activity against gut flora. It is in the lead optimization stage, with an IND application expected in 2026.

TNBi-2, a multi-target conjugate drug, targets nontuberculous mycobacterial pulmonary disease (NTM-PD), aiming to simplify treatment and reduce resistance rates. It is in lead optimization, with an IND planned for 2027.

TNBm-1, a bifunctional small molecule, targets both gut bacterial metabolic pathways and host nuclear receptors for metabolic disease treatment. It is in the lead identification stage, with an IND expected in 2028.

Despite a promising pipeline, DanNuo has no approved commercial products and has generated no product sales revenue, recording net losses consistently. For 2023, 2024, and the first nine months of 2025 (the reporting period), net losses were RMB 192 million, RMB 146 million, and RMB 116 million, respectively, primarily due to high R&D expenses and increased administrative costs.

The company also received government grants during the period: RMB 4.444 million in 2023, RMB 4.938 million in 2024, and RMB 1.181 million in the first nine months of 2025, along with minor gains from financial assets like structured deposits and bank interest income.

Notably, DanNuo has high supplier concentration and relies on third-party manufacturing. Purchases from the top five suppliers amounted to RMB 41.655 million, RMB 32.992 million, and RMB 10.767 million during the reporting periods, accounting for 49.5%, 80.8%, and 70% of annual procurement, respectively.

The largest supplier sequentially was a Shanghai-based CRO service company; a Chongqing-based, Shenzhen-listed CDMO service provider; and a global CRDMO listed in Shanghai and Hong Kong with operations across Asia, Europe, and North America. Purchases from the largest supplier were RMB 17.321 million, RMB 17.9 million, and RMB 6.283 million, representing 20.6%, 43.8%, and 40.8% of annual procurement.

The company relies on third parties for manufacturing clinical and commercial supplies. Failure of third-party facilities to gain regulatory approval or quality issues during production could significantly adversely affect the business.

Regarding production, the company currently has no in-house manufacturing facilities, depending on CDMO partners for clinical-stage and initial commercial supply. Its own cGMP-standard facility is expected to be operational only in 2028. If third parties fail to supply sufficient quantities of qualified drugs at reasonable prices, commercialization could be impacted.

R&D-intensive biotech companies inherently face high risks. Although core products are advanced, clinical development outcomes are uncertain, and patent protection faces challenges. As of the latest practicable date, 14 of the company's substance composition patents have expired, with one expiring in 2028. While protection is supplemented by patents for use and formulation, competition from generics remains a possibility.

R&D spending at DanNuo has shown a declining trend. During the reporting periods, R&D expenses were RMB 108 million, RMB 69.838 million, and RMB 46.395 million, accounting for 84.8%, 84.2%, and 56.2% of total operating expenses, respectively. Core products TNP-2198 and TNP-2092 injection were the focus, together constituting 91.9%, 91.9%, and 83.1% of total R&D spending, highlighting the company's focus on commercializing its core pipeline.

Financially, total liabilities were RMB 855 million and RMB 1.031 billion in 2023 and 2024, against total assets of RMB 96.054 million and RMB 133 million, resulting in debt-to-asset ratios of 890.09% and 775.8%. As of September 30, 2025, total liabilities were RMB 88.242 million against total assets of RMB 266 million, significantly reducing the ratio to 33.21%, primarily due to the derecognition of redeemed liabilities and cash inflows from Series E2 and E3 financing.

Net cash flow from operating activities was consistently negative: RMB -98.116 million, RMB -48.601 million, and RMB -69.451 million for the respective periods. Net cash flow from financing activities was positive: RMB 4.726 million, RMB 88.497 million, and RMB 191 million. As of the end of the first nine months of 2025, cash and cash equivalents increased to RMB 222 million, providing funding support for subsequent R&D and commercialization.

To advance core product commercialization, DanNuo has entered an exclusive commercialization cooperation agreement with Grand Life Sciences for the marketing, promotion, and distribution of TNP-2198 in Greater China (excluding Taiwan).

The agreement involves Grand Life Sciences paying up to RMB 775 million, including an exclusive upfront fee of RMB 25 million, two-tranche milestone payments, and sales-based milestone payments. DanNuo will pay corresponding promotion service fees, initially at 75%, gradually reducing to 65%.

Subsequent milestone payments are structured. First, commercialization milestone payments total RMB 65 million, triggered upon obtaining marketing authorization in China for the first indication and inclusion in the National Reimbursement Drug List (NRDL). Second, promotion milestone payments up to RMB 71 million are payable in six tranches based on cumulative annual net sales thresholds. Additionally, promotion incentive payments up to RMB 20 million are payable in two tranches after first achieving specified annual net sales thresholds.

However, the cooperation includes clear performance constraints. If DanNuo fails to obtain marketing authorization in China for the first indication of TNP-2198 by December 31, 2026, Grand Life Sciences can unilaterally terminate the agreement, and DanNuo must refund the received first milestone payment. If the product is not included in the 2027 NRDL, the partner can request renegotiation of terms; failure to reach agreement may lead to termination.

Beyond partnership risks, DanNuo's commercialization faces multiple challenges. Firstly, sales and distribution capabilities are underdeveloped. The company has focused primarily on R&D since inception, lacking an in-house sales and marketing team and commercialization experience, relying heavily on Grand Life Sciences's network. The prospectus highlights the risk that, for future global distribution, significant resources would be needed to build an internal marketing organization and sales team, competing for talent with established pharmaceutical companies.

Market acceptance is uncertain, as existing bacterial control therapies are widely adopted by the medical community. Acceptance by doctors, patients, and payers for new products is not guaranteed. Guidelines or studies published by professional associations or government agencies could also negatively impact product use.

Regarding reimbursement, drug pricing is subject to government regulation. Inclusion in the NRDL directly affects market penetration. Even if included, significant price reductions may pressure profit margins.

On compliance and operations, the company has a compliance flaw related to unregistered lease agreements, though expected fines are minor, administrative risks exist. Data accuracy in R&D, regulatory approval of manufacturing facilities, and intellectual property protection could also significantly impact the business. Furthermore, continuous losses since founding mean future inability to achieve profitability through product sales would create ongoing funding pressure.

DanNuo has completed seven financing rounds since establishment, with investors including Northern Light Venture Capital, Origin Ventures, and Gaotejia Investment. The post-money valuation after the last round was RMB 2.013 billion, providing crucial funding for pipeline R&D and commercialization preparation.

Regarding shareholding structure, as of the latest practicable date, the Cumbre entity group was the single largest shareholder group, exercising approximately 18.82% of the voting rights. This group is a passive financial investor not involved in daily operations. Company founder, Chairman, and CEO Dr. Ma Zhenkun, together with the ESOP platform, controls approximately 13.61% of the voting rights. Dr. Ma has over 30 years of experience in infectious disease drug development and is a core management figure.